Paradigm reports 6.1% stake in Maze Therapeutics

Maze Therapeutics, Inc. ownership disclosure: Paradigm BioCapital Advisors LP group reports beneficial ownership stakes in Common Stock as of March 25, 2026.

Accepted by SEC EDGAR 04/01/2026 - 04:00 PM EDT Learn about SEC filing dates

Rhea-AI Filing Summary

Maze Therapeutics, Inc. ownership disclosure: Paradigm BioCapital Advisors LP group reports beneficial ownership stakes in Common Stock as of March 25, 2026. The filing lists 3,051,087 shares (6.1%) held by Paradigm BioCapital Advisors/related reporting persons and 2,688,520 shares (5.4%) held by Paradigm BioCapital International Fund Ltd. Shares outstanding were 49,708,658 as of March 20, 2026.

The filing clarifies voting and dispositive power is sole for the reported shares and includes a joint filing agreement signed by the reporting persons.

Insights

Institutional Ownership Analyst

Paradigm group holds low single-digit stakes in Maze Therapeutics; disclosures show sole voting and dispositive power.

The Schedule 13G lists 3,051,087 shares (6.1%) for Paradigm BioCapital Advisors/related persons and 2,688,520 shares (5.4%) for the Paradigm fund, using an issuer outstanding base of 49,708,658 shares as of March 20, 2026. This establishes visible institutional positions without change-of-control language.

Ownership is presented as beneficial with sole voting/dispositive power. Subsequent filings may show changes in position; any material adjustments would appear in later beneficial ownership reports.

Key Figures

Paradigm BioCapital Advisors holdings: 3,051,087 shares Paradigm BioCapital Advisors ownership %: 6.1% Paradigm BioCapital International Fund holdings: 2,688,520 shares +3 more

6 metrics

Paradigm BioCapital Advisors holdings 3,051,087 shares reported beneficially owned as of March 25, 2026

Paradigm BioCapital Advisors ownership % 6.1% percent of Common Stock based on 49,708,658 outstanding

Paradigm BioCapital International Fund holdings 2,688,520 shares reported beneficially owned as of March 25, 2026

Paradigm Fund ownership % 5.4% percent of Common Stock based on 49,708,658 outstanding

Shares outstanding used 49,708,658 shares outstanding as of March 20, 2026 (used to compute percentages)

CUSIP 578784100 Maze Therapeutics Common Stock CUSIP on cover page

Key Terms

Schedule 13G, beneficially own, sole dispositive power, joint filing agreement

4 terms

Schedule 13G regulatory

"This is filed by the following (the "Reporting Persons"):"

A Schedule 13G is a formal document that investors file with the government when they acquire a large ownership stake in a company, usually for investment purposes rather than control. It helps keep the public informed about who owns significant parts of a company's shares, which can influence how the company is managed and how investors make decisions. Filing this schedule is important for transparency and understanding the ownership landscape of publicly traded companies.

beneficially own financial

"directly beneficially own the Common Stock reported in this statement"

Beneficially own means having the economic rights and risks of a security—such as the right to receive dividends, sell the shares, or profit from price changes—whether or not your name appears on the official share register. Think of it like renting a car: you use it and reap the benefits even if the title lists someone else. Investors care because beneficial ownership determines who truly controls value, must be disclosed under securities rules, and can signal potential influence or trading activity that affects a stock’s price.

sole dispositive power regulatory

"Sole Dispositive Power 3,051,087.00"

Sole dispositive power is the exclusive legal authority to decide what happens to a security — for example, whether to sell, transfer, or retain shares — without needing anyone else’s permission. Investors care because it signals who truly controls the economic outcome of an investment: like holding the only key to a safe, the holder can realize gains or losses and may trigger regulatory reporting, insider rules, or influence over corporate ownership.

joint filing agreement regulatory

"Exhibit 99.1 - Joint Filing Agreement"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What stake does Paradigm BioCapital report in MAZE?

Paradigm BioCapital reports beneficial ownership of 3,051,087 shares (6.1%). The filing ties percentages to 49,708,658 shares outstanding as of March 20, 2026, and states sole voting and dispositive power for those shares.

How many shares does Paradigm BioCapital International Fund hold in MAZE?

The Paradigm BioCapital International Fund reports holding 2,688,520 shares (5.4%). The amount is disclosed on the cover page and used in the Schedule 13G ownership calculation dated March 25, 2026.

What voting and disposition rights are disclosed in this 13G?

The reporting persons state they have sole voting and sole dispositive power over the reported shares. The cover-page entries list sole voting and sole dispositive power for each reported holding.

What outstanding share count does the filing use to calculate percentages?

Percentages are based on 49,708,658 shares outstanding as of March 20, 2026. That figure is cited in the Schedule 13G and used to compute the reported ownership percentages.

Who are the filing parties for this Schedule 13G on MAZE?

This Schedule 13G is filed by Paradigm BioCapital Advisors LP, Paradigm BioCapital Advisors GP LLC, Senai Asefaw, M.D., and Paradigm BioCapital International Fund Ltd. A joint filing agreement is included as Exhibit 99.1.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

SCHEDULE 13G

UNDER THE SECURITIES EXCHANGE ACT OF 1934

Maze Therapeutics, Inc.

(Name of Issuer)

Common Stock, $0.001 par value per share

(Title of Class of Securities)

578784100

(CUSIP Number)

03/25/2026

(Date of Event Which Requires Filing of this Statement)

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

Rule 13d-1(b)

Rule 13d-1(c)

Rule 13d-1(d)

schemaVersion:

SCHEDULE 13G

CUSIP Number(s): 578784100

1

Names of Reporting Persons

Paradigm BioCapital Advisors LP

2

Check the appropriate box if a member of a Group (see instructions)

(a)
(b)

3

Sec Use Only

4

Citizenship or Place of Organization

DELAWARE

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 3,051,087.00
6	Shared Voting Power 0.00
7	Sole Dispositive Power 3,051,087.00
8	Shared Dispositive Power 0.00

9

Aggregate Amount Beneficially Owned by Each Reporting Person

3,051,087.00

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11

Percent of class represented by amount in row (9)

6.1 %

12

Type of Reporting Person (See Instructions)

PN

SCHEDULE 13G

CUSIP Number(s): 578784100

1

Names of Reporting Persons

Paradigm BioCapital Advisors GP LLC

2

Check the appropriate box if a member of a Group (see instructions)

(a)
(b)

3

Sec Use Only

4

Citizenship or Place of Organization

DELAWARE

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 3,051,087.00
6	Shared Voting Power 0.00
7	Sole Dispositive Power 3,051,087.00
8	Shared Dispositive Power 0.00

9

Aggregate Amount Beneficially Owned by Each Reporting Person

3,051,087.00

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11

Percent of class represented by amount in row (9)

6.1 %

12

Type of Reporting Person (See Instructions)

OO

Comment for Type of Reporting Person: limited liability company

SCHEDULE 13G

CUSIP Number(s): 578784100

1

Names of Reporting Persons

Senai Asefaw, M.D.

2

Check the appropriate box if a member of a Group (see instructions)

(a)
(b)

3

Sec Use Only

4

Citizenship or Place of Organization

UNITED STATES

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 3,051,087.00
6	Shared Voting Power 0.00
7	Sole Dispositive Power 3,051,087.00
8	Shared Dispositive Power 0.00

9

Aggregate Amount Beneficially Owned by Each Reporting Person

3,051,087.00

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11

Percent of class represented by amount in row (9)

6.1 %

12

Type of Reporting Person (See Instructions)

IN

SCHEDULE 13G

CUSIP Number(s): 578784100

1

Names of Reporting Persons

Paradigm BioCapital International Fund Ltd.

2

Check the appropriate box if a member of a Group (see instructions)

(a)
(b)

3

Sec Use Only

4

Citizenship or Place of Organization

CAYMAN ISLANDS

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 2,688,520.00
6	Shared Voting Power 0.00
7	Sole Dispositive Power 2,688,520.00
8	Shared Dispositive Power 0.00

9

Aggregate Amount Beneficially Owned by Each Reporting Person

2,688,520.00

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11

Percent of class represented by amount in row (9)

5.4 %

12

Type of Reporting Person (See Instructions)

CO

SCHEDULE 13G

Item 1.
(a)	Name of issuer: Maze Therapeutics, Inc.
(b)	Address of issuer's principal executive offices: 171 Oyster Point Blvd., Suite 300, South San Francisco, CA 94080
Item 2.
(a)	Name of person filing: This Schedule 13G is filed by the following (the "Reporting Persons"): (1) Paradigm BioCapital Advisors LP (the "Adviser"); (2) Paradigm BioCapital Advisors GP LLC (the "Adviser GP"); (3) Senai Asefaw, M.D. ("Senai Asefaw"); and (4) Paradigm BioCapital International Fund Ltd. (the "Fund"). The Fund is a private investment vehicle. The Fund and one or more separately managed accounts managed by the Adviser (the "Account") directly beneficially own the Common Stock reported in this statement. The Adviser is the investment manager of the Fund and the Account. The Adviser GP is the general partner of the Adviser. Senai Asefaw is the managing member of the Adviser GP. The Adviser, the Adviser GP and Senai Asefaw may be deemed to beneficially own the Common Stock directly beneficially owned by the Fund and the Account. Each Reporting Person disclaims beneficial ownership with respect to any Common Stock other than the Common Stock directly beneficially owned by such Reporting Person.
(b)	Address or principal business office or, if none, residence: The principal business office of the Fund is c/o Walkers, 190 Elgin Avenue, George Town, Grand Cayman KY1-9001, Cayman Islands. The principal business office of the Adviser, the Adviser GP and Senai Asefaw is 767 Third Avenue, 17th Floor, New York, NY 10017.
(c)	Citizenship: For citizenship or place of organization see Item 4 of the cover page of each Reporting Person.
(d)	Title of class of securities: Common Stock, $0.001 par value per share
(e)	CUSIP Number(s): 578784100
Item 3.	If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
(a)	Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
(b)	Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
(c)	Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
(d)	Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
(e)	An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
(f)	An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
(g)	A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
(h)	A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
(i)	A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
(j)	A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J), please specify the type of institution:
(k)	Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).
Item 4.	Ownership
(a)	Amount beneficially owned: See Item 9 on the cover page for each Reporting Person, and Item 2, which information is given as of the close of business on March 25, 2026.
(b)	Percent of class: See Item 11 on the cover page for each Reporting Person. The percentages of beneficial ownership contained herein are based on 49,708,658 shares of Common Stock outstanding as of March 20, 2026, as reported by the Issuer in its Form 10-K filed with the SEC on March 25, 2026.
(c)	Number of shares as to which the person has:
	(i) Sole power to vote or to direct the vote: See Item 5 on the cover page for each Reporting Person.
	(ii) Shared power to vote or to direct the vote: See Item 6 on the cover page for each Reporting Person.
	(iii) Sole power to dispose or to direct the disposition of: See Item 7 on the cover page for each Reporting Person.
	(iv) Shared power to dispose or to direct the disposition of: See Item 8 on the cover page for each Reporting Person.
Item 5.	Ownership of 5 Percent or Less of a Class.
	Not Applicable
Item 6.	Ownership of more than 5 Percent on Behalf of Another Person.
	Not Applicable
Item 7.	Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
	Not Applicable
Item 8.	Identification and Classification of Members of the Group.
	Not Applicable
Item 9.	Notice of Dissolution of Group.
	Not Applicable

Item 10.

Certifications:

By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under ?? 240.14a-11.

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

Paradigm BioCapital Advisors LP

Signature:	/s/ David K. Kim
Name/Title:	David K. Kim / Authorized Signatory
Date:	04/01/2026

Paradigm BioCapital Advisors GP LLC

Signature:	/s/ David K. Kim
Name/Title:	David K. Kim / Authorized Signatory
Date:	04/01/2026

Senai Asefaw, M.D.

Signature:	/s/ Senai Asefaw, M.D.
Name/Title:	N/A
Date:	04/01/2026

Paradigm BioCapital International Fund Ltd.

Signature:	/s/ David K. Kim
Name/Title:	David K. Kim / Authorized Signatory
Date:	04/01/2026

Exhibit Information

Exhibit 99.1 - Joint Filing Agreement.